Guest guest Posted May 3, 2012 Report Share Posted May 3, 2012 Hi everyone, I must admit that I haven't been around for quite a while but I wanted to run something past you all, maybe you already know about this so excuse me for not knowing because of my lack of reading posts from you, for that I apologize. I'm possibly (if they let me) going to be in a study with teleprivar (sp)and something that they call VX-222. It is a new drug in a phase II study. There will be 5-10 people here at the UW-Madison and 150 people throughout the USA and 10 other countries. My question is, has anyone heard of this? It's sponsored by Vertex. It will be a 12, 24, or 48 week treatment, depending on which group I will be in. I have a lot of other health problems aside from the hepc so I don't know if I will qualify. It is for genotype 1 people with cirrhosis (which I'm not sure I have yet) who were responders who relapsed (that's me). I did treatment from 2010 - 2011, 63 weeks on just the RIBA and IFN. What do you all think about me being in this study. The last treatment just about killed me with 10 rbc transfusions because I was sooo anemic. My WBC's were also VERY low....down to .90....should be above 3.4 or something like that. Anyway, I would be very much appreciative if anyone can comment on this or if anyone has been in a study with the new drug, VX-222. Thanks for reading, Barb Z Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.